Chongqing Peg-bio Biopharm Co., Ltd.

This phase IIa trial tests whether FT1, a lab-made version of a natural gut hormone, is safe and helps reduce fluid loss in adults with short bowel syndrome. Participants receive weekly injections of FT1 or a placebo for five weeks. The study measures changes in stool weight and …

This phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…

This early-stage trial tests an experimental drug called PL54 in adults aged 18 to 55 with phenylketonuria (PKU), a genetic disorder that prevents the body from breaking down the amino acid phenylalanine. PL54 is an enzyme designed to help lower high blood phenylalanine levels, w…

This study tests a drug called PJ009 in people aged 14 and older with short bowel syndrome who rely on IV nutrition. The goal is to see if daily shots can safely reduce the amount of IV nutrition needed. Participants will receive either PJ009 or a placebo for 24 weeks, then all w…

This early-stage trial is testing a new drug called PN20 in 12 adults with primary immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, raising bleeding risk. Participants receive a single injection of PN20, which is designed to stimulate platele…

This study tests a single injection of PN20, a lab-made protein, to see if it can safely raise platelet counts in adults with chronic liver disease who have low platelets and are scheduled for a minor procedure. About 54 participants will receive either PN20 or a placebo. The mai…